Shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE – Get Free Report) have been given an average rating of “Moderate Buy” by the seven ratings firms that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.00.
Several equities research analysts have recently issued reports on ATHE shares. Lake Street Capital assumed coverage on shares of Alterity Therapeutics in a research report on Tuesday, September 15th. They issued a “buy” rating and a $10.00 price objective for the company. UBS Group set a $12.00 target price on shares of Alterity Therapeutics in a report on Tuesday, August 11th. Weiss Ratings cut shares of Alterity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, November 4th. Finally, Craig Hallum set a $2.00 price target on Alterity Therapeutics in a report on Tuesday, August 11th.
Get Our Latest Stock Analysis on Alterity Therapeutics
Institutional Investors Weigh In On Alterity Therapeutics
Alterity Therapeutics Price Performance
ATHE stock opened at $1.52 on Thursday. Alterity Therapeutics has a 52 week low of $1.52 and a 52 week high of $5.89. The company’s 50-day moving average price is $2.78 and its 200 day moving average price is $3.88.
Alterity Therapeutics (NASDAQ:ATHE – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($0.28) EPS for the quarter. The company had revenue of $0.31 million for the quarter. On average, research analysts expect that Alterity Therapeutics will post -0.12 earnings per share for the current fiscal year.
About Alterity Therapeutics
Alterity Therapeutics is an Australian clinical-stage biotechnology company developing treatments for neurodegenerative diseases. Its research focuses on conditions associated with abnormal protein accumulation and disrupted iron balance in the brain, including multiple system atrophy (MSA) and Parkinson’s disease. The company’s lead candidate, ATH434, is an investigational small-molecule therapy being studied for MSA. Alterity is evaluating the treatment in clinical trials; it is not an approved medicine.
See Also
- Five stocks we like better than Alterity Therapeutics
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Alterity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alterity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
